Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Curexo Inc. (060280.KQ)
CUREXO, Inc. specializes in the creation and distribution of medical technology. The company's activities are organized across three primary divisions: Medical Robot, Implant, and Trade. Its Medical Robot segment focuses on advanced robotic systems designed for surgical procedures, such as joint replacement and spinal operations, in addition to rehabilitation robots and other specialized medical devices. The Implant division is dedicated to manufacturing artificial joint prostheses and a range of other internal body implants. A unique aspect of the company is its Trade division, which manages the import and sale of food products. CUREXO was established on February 29, 1992, and its main offices are situated in Seoul, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.65% | -14.28% | -30.04% | -32.14% | -3.43% | -15.22% | +23.32% | +11.72% | +15.42% | +84.48% | +227.56% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+34.2% ★ Q1'26: -18.3% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%+131.9% ★ Q1'26: -58.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-20.5% Q1'26: +9.6% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+3.2% Q1'26: -5.7% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+3.0% Q1'26: -4.7% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+0.0% ★ Q1'26: +1.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×0.23× ★ Q1'26: -1.08× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
39.28B
est: 39.00B (+0.7%)
|
42.79B
est: 48.40B (-11.6%)
|
64.99B
est: 34.00B (+91.1%)
|
72.88B
est: 73.00B (-0.2%)
|
55.53B
est: 75.60B (-26.5%)
|
74.54B
est: 74.70B (-0.2%)
|
85.00B
85.00B – 85.00B
+13.8% YoY
|
96.00B
96.00B – 96.00B
+12.9% YoY
|
| EBITDA |
1.09B
est: -1.11B (+197.9%)
|
-567.20M
est: -1.38B (+58.8%)
|
-236.42M
est: -968.02M (+75.6%)
|
-2.75B
est: -2.08B (-32.5%)
|
-6.41B
est: -1.53B (-319.5%)
|
5.15B
est: -1.51B (+441.1%)
|
-1.72B
-1.72B – -1.72B
-13.8% YoY
|
-1.94B
-1.94B – -1.94B
-12.9% YoY
|
| EBIT |
445.25M
est: -2.04B (+121.8%)
|
-2.04B
est: -2.53B (+19.3%)
|
-1.48B
est: -1.78B (+16.6%)
|
-4.35B
est: -3.82B (-13.7%)
|
-8.57B
est: -3.65B (-134.9%)
|
2.36B
est: -3.61B (+165.5%)
|
-4.10B
-4.10B – -4.10B
-13.8% YoY
|
-4.63B
-4.63B – -4.63B
-12.9% YoY
|
| Net Income |
416.63M
est: 287.57M (+44.9%)
|
-2.34B
est: 6.41B (-136.5%)
|
-3.04B
est: -31.92B (+90.5%)
|
-4.86B
|
-8.76B
est: 4.48B (-295.5%)
|
2.78B
est: 2.67B (+4.2%)
|
7.03B
7.03B – 7.03B
+163.1% YoY
|
8.38B
8.38B – 8.38B
+19.3% YoY
|
| SGA |
3.86B
est: 3.75B (+2.9%)
|
2.33B
est: 4.65B (-50.0%)
|
3.05B
est: 3.27B (-6.7%)
|
4.75B
est: 7.02B (-32.3%)
|
4.73B
est: 4.78B (-1.0%)
|
4.82B
est: 4.73B (+2.0%)
|
5.38B
5.38B – 5.38B
+13.8% YoY
|
6.07B
6.07B – 6.07B
+12.9% YoY
|
| EPS |
12.49
est: 7.00 (+78.4%)
|
-70.13
est: 156.00 (-145.0%)
|
-84.00
est: -777.00 (+89.2%)
|
-120.00
|
-212.55
est: 109.00 (-295.0%)
|
67.76
est: 65.00 (+4.2%)
|
171.00
171.00 – 171.00
+163.1% YoY
|
204.00
204.00 – 204.00
+19.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive team data is not available for this company yet.
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 060280.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
